Publications
Detailed Information
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Ro, Jungsil | - |
dc.contributor.author | Lee, Eun Sook | - |
dc.contributor.author | Kwon, Youngmee | - |
dc.contributor.author | Ahn, Jin-Hee | - |
dc.contributor.author | Ahn, Jin Seok | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Kang, Han Sung | - |
dc.contributor.author | Shin, Kyung Hwan | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Park, In-Ae | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Im, Young Hyuck | - |
dc.contributor.author | Ha, Sung Whan | - |
dc.date.accessioned | 2022-03-22T09:09:47Z | - |
dc.date.available | 2022-03-22T09:09:47Z | - |
dc.date.created | 2021-01-13 | - |
dc.date.created | 2021-01-13 | - |
dc.date.created | 2021-01-13 | - |
dc.date.created | 2021-01-13 | - |
dc.date.issued | 2012-04 | - |
dc.identifier.citation | Breast Cancer Research and Treatment, Vol.132 No.2, pp.589-600 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.other | 120797 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177183 | - |
dc.description.abstract | An addition of trastuzumab preoperatively to chemotherapy for human epidermal growth factor receptor 2 (HER2) positive breast cancer improved relapse-free survival (RFS). This study was designed to evaluate the efficacy and safety of preoperative paclitaxel, gemcitabine, and trastuzumab (PGH) combination for HER2-positive breast caner. Pathologically, proven node positive stage II/III breast cancer patients with adequate organ function and no history of anti-cancer therapy were eligible. Patients received weekly trastuzumab with paclitaxel 80 mg/m(2) and gemcitabine 1,200 mg/m(2) on days 1 and 8, every 3 weeks for 6 cycles. Postoperatively, patients completed trastuzumab for 1 year and hormone therapy for 5 years if indicated. All patients received postoperative radiation therapy. Of 53 enrolled patients with a median tumor of 5.3 (range, 2.0 to > 12) cm; 43.4%, T3/T4; 75.4%, N2/N3; and 45.3%, positive hormone receptors. The pathologic complete response (pCR) rate was 58.5% in both tumor and lymph nodes. Grade 3/4 adverse events were neutropenia (32%), febrile neutropenia (0.6%), and transient elevation of AST/ALT (1.6%) during a total of 318 cycles. All patients maintained normal cardiac function. With a median follow-up of 40 months, 3-year RFS rate was 84% with 91.7% distant metastasis-free survival rates. Remarkable pCR rate was obtained with non-anthracycline-based PGH therapy for HER2-positive stage II/III breast cancer. Adverse events were mild with few incidences of febrile neutropenia. | - |
dc.language | 영어 | - |
dc.publisher | Kluwer Academic Publishers | - |
dc.title | Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01 | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s10549-011-1852-0 | - |
dc.citation.journaltitle | Breast Cancer Research and Treatment | - |
dc.identifier.wosid | 000301545900021 | - |
dc.identifier.scopusid | 2-s2.0-84859102946 | - |
dc.citation.endpage | 600 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 589 | - |
dc.citation.volume | 132 | - |
dc.identifier.sci | 000301545900021 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Noh, Dong-Young | - |
dc.contributor.affiliatedAuthor | Park, In-Ae | - |
dc.contributor.affiliatedAuthor | Ha, Sung Whan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | PATHOLOGICAL COMPLETE REMISSION | - |
dc.subject.keywordPlus | SURGICAL ADJUVANT BREAST | - |
dc.subject.keywordPlus | NEOADJUVANT THERAPY | - |
dc.subject.keywordPlus | COMPARING DOXORUBICIN | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | EPIRUBICIN | - |
dc.subject.keywordPlus | LEUKEMIA | - |
dc.subject.keywordAuthor | Preoperative chemotherapy | - |
dc.subject.keywordAuthor | Trastuzumab | - |
dc.subject.keywordAuthor | Paclitaxel | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | HER2-positive Breast Cancer | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.